Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

The Journal of antimicrobial chemotherapy - 1 Aug 2007

Mushtaq Shazad, Warner Marina, Ge Yigong, Kaniga Koné, Livermore David M

Abstract excerpt

BACKGROUND: Ceftaroline (PPI-0903M, T-91825) is a novel cephalosporin, administered as an N-phosphono prodrug. We investigated its in vitro activity and resistance selection potential. METHODS: MICs were determined by CLSI agar dilution, but with varied inocula. Mutant selection was investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acinetobacter
Share to Bacteroides
Share to Cephalosporins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clavulanic Acid

Share to Enterococcus

Share to Gram-Negative Bacteria

Share to Respiratory Tract Diseases

Share to Staphylococcus

Source

Identifiers

PMID: 17548456
DOI: 10.1093/jac/dkm150

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17548456-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.PMID 17548456Read ↗

In vitro activity of ceftaroline and comparator antimicrobials against European and Middle East isolates from complicated skin and skin-structure infections collected in 2008-2009.Semantic proximity Read ↗

In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United StatesSemantic proximity Read ↗

In vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during a national survey conducted in Belgian hospitals.Semantic proximity Read ↗

Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspectiveSemantic proximity Read ↗

In Vitro Assessment of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates in a Tertiary Care Hospital in PakistanSemantic proximity Read ↗

Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.Semantic proximity Read ↗

Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.Semantic proximity Read ↗

Potential of Staphylococcus aureus isolates carrying different PBP2a alleles to develop resistance to ceftaroline.Semantic proximity Read ↗

Pre-Use Susceptibility to Ceftaroline in Clinical Staphylococcus aureus Isolates from Germany: Is There a Non-Susceptible Pool to be Selected?Semantic proximity Read ↗

Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.Semantic proximity Read ↗

The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.Semantic proximity Read ↗

Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.